Boehringer Banks on New Lung Fibrosis Drug Being a Game Changer
The experimental treatment, called nerandomilast, slowed lung-function decline in patients with two forms of organ scarring in a pair of advanced studies, the company said Monday.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Why Privia Health (PRVA) Stock Is Up Today
What Happened? Shares of healthcare tech company Privia Health Group (NASDAQ:PRVA) jumped 3.4% in the morning session as investors anticipated a heavy week of corporate earnings. There was no company-specific news to explain the move, suggesting the physician enablement company's stock was lifted by positive sentiment in the wider market. U.S. stock futures pointed to a higher open, with major indices edging up in early trading. This upbeat mood came as Wall Street braced for a significant number of earnings reports from major U.S. companies. Notably, the earnings season got off to a strong start: More than 85% of the S&P 500 stocks that reported earnings exceeded expectations, according to FactSet data. This robust performance fueled positive sentiment, suggesting that corporate profitability remained resilient despite ongoing economic uncertainties. After the initial pop the shares cooled down to $19.93, up 1.6% from previous close. Is now the time to buy Privia Health? Access our full analysis report here, it's free. What Is The Market Telling Us Privia Health's shares are somewhat volatile and have had 12 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 3 days ago when the stock dropped 5.2% as several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like Elevance Health and Humana seeing declines due to an analyst downgrade and a lost lawsuit regarding Medicare bonus payments, respectively. Additionally, some pharmaceutical and biotech companies experienced sharp drops following unfavorable news; for instance, Sarepta Therapeutics plunged after a report indicated another patient death tied to its experimental gene therapy, and GSK's blood cancer drug dosage was voted against by the FDA advisory committee. Broader market sentiment, including concerns about rising costs and inadequate pricing for 2025 plans among health insurers, also contributed to the downward pressure on healthcare equities. Privia Health is up 1.5% since the beginning of the year, but at $19.93 per share, it is still trading 22.4% below its 52-week high of $25.69 from March 2025. Investors who bought $1,000 worth of Privia Health's shares at the IPO in April 2021 would now be looking at an investment worth $573.53. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Sotera Health Company (SHC) Stock Trades Up, Here Is Why
What Happened? Shares of healthcare services company Sotera Health (NASDAQ:) jumped 3.4% in the morning session after the stock gained ground amid broader positive market sentiment ahead of a busy week for corporate earnings. U.S. stock futures indicated a higher open for the markets, setting a positive tone for investors who were anticipating a heavy slate of earnings reports from major companies during the week. Notably, the earnings season got off to a strong start: More than 85% of the S&P 500 stocks that reported earnings exceeded expectations, according to FactSet data. This robust performance fueled positive sentiment, suggesting that corporate profitability remained resilient despite ongoing economic uncertainties. After the initial pop the shares cooled down to $11.06, down 0.1% from previous close. Is now the time to buy Sotera Health Company? Access our full analysis report here, it's free. What Is The Market Telling Us Sotera Health Company's shares are somewhat volatile and have had 11 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The biggest move we wrote about over the last year was 3 months ago when the stock gained 5.9% on the news that Goldman Sachs analyst Matthew Sykes upgraded the stock from Neutral to Buy and raised the price target from $14 to $17. Sykes emphasized that SHC's consistent exposure to the commercial pharmaceutical and medical device sectors, both of which are considered essential and relatively insulated from economic cycles, positions the company as a more compelling investment amid growing macroeconomic uncertainty. Sotera Health Company is down 18.8% since the beginning of the year, and at $11.06 per share, it is trading 34.6% below its 52-week high of $16.91 from September 2024. Investors who bought $1,000 worth of Sotera Health Company's shares at the IPO in November 2020 would now be looking at an investment worth $440.64. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
B.C. NDPers try to cast themselves as the good guys in reversal over pricy drug
VICTORIA — NDP MLA Ravi Parmar was quick to claim a share of the credit last week for restoring drug coverage for Charleigh Pollock, the 10-year-old Langford girl ravaged by a rare terminal disease. 'From the very first day Charleigh's family reached out, my office and I have advocated for her as we do for all constituents, with respect, compassion, and in confidence,' the Langford-Highlands MLA wrote Friday on his social media account. That was not the view of Charleigh's mother, Jori Fales, who led the fight on the girl's behalf since the threat to cut off her coverage materialized back in February. 'He (Parmar) called once in February when we started our appeal,' Fales said on social media. 'There's been no communication since February except when I emailed Mr. Parmar June 27 asking for his urgent help. 'He responded saying he was glad I'll have the opportunity to meet with Josie Osborne,' he said, referring to a meeting with the health minister on July 4. The public record discloses little other evidence to support Parmar's claim of 'steadfast' advocacy over the six months. When he did weigh in, it was mostly to repeat the government line that decisions on funding expensive drugs for rare diseases — like Brineura, the only treatment for Charleigh's Batten disease — must be left up to the 'medical experts.' Parmar's most recent posting said 'the medical experts who reviewed this case agree: sadly, at this stage of Charleigh's disease, Brineura no longer offers a clinical benefit.' That claim was disputed by numerous experts in Batten disease, something the government finally acknowledged in restoring funding last week. Perhaps the key to understanding the victory lap Parmar took Friday was the claim that his advocacy was undertaken 'in confidence.' Publicly he echoed the premier and the health minister about not overruling the province's hand-picked medical experts. But all the while, he was fighting the good fight on Charleigh's behalf behind the scenes — or so he'd have us believe. 'The case involving Charleigh Pollock has been one of the most difficult I've faced in my many years of service to my community,' said Parmar. 'It is complex, emotional, and at its core, heartbreaking.' Almost as if he were the victim, no? Parmar's self-serving statement might placate some gullible NDP supporters. But for those wondering how the NDP picked a fight it could not win with an ailing 10-year-old, consider the widespread silence of New Democrats on an issue where they knew their government was wrong, wrong, wrong. Nor was Parmar's claim that he'd always been there for Charleigh and her family the most preposterous utterance in this affair. That nod would go to Premier David Eby, when he defended the system that led the province to cut off funding for the only medication that could mitigate the severe seizures associated with Batten disease. 'These are profound and awful decisions that have to be made by experts and physicians and not by politicians,' Eby told reporters last month. 'It doesn't make any sense for that family. I recognize that. But I also recognize that the other course is, if I can say it — is actually worse.' No, you can't say that. Not when the premier's initial deference to provincially selected experts relegated Charleigh's family to raising money over the internet to pay for the one drug that offered the little girl relief in the time she has left. As for Parmar, he may be in line for another kind of relief in his capacity as minister of forests. His mandate letter from the premier directs him to 'work toward a harvest of 45 million cubic metres per year,' from provincial forests, a 50 per cent increase over last year's harvest. The target was discounted as unlikely to be achieved, owing to permitting, regulations, Indigenous approvals and other obstacles. Finance Minister Brenda Bailey signalled her doubts in the provincial budget, forecasting a status quo timber harvest of 30 million cubic metres this year and next, followed by a reduction to 29 million in 2027. Now recent events on the trade front may provide Parmar with an out. Premier David Eby and Prime Minister Mark Carney both said last week that Canada may be able to settle the long-running softwood lumber dispute with a quota system. Canada would try to head off or reduce tariffs — currently 14.38 per cent and headed for 34.45 per cent — by capping soft lumber exports to the U.S. Parmar was quick to embrace the quota option. 'It just may be able to address this issue once and for all,' the forests minister told Mark Page of Black Press Media last week. Then again, 'the president seems to really like tariffs and, so, he may say, bugger off,' Parmar acknowledged. Still, the quota option could provide Parmar with an excuse for giving up on the 50 per cent increase in harvesting. B.C. supplies about 40 per cent of this country's lumber exports to the U.S. and would presumably have to absorb its share of any cap on exports. The cap would in turn reduce the need for any increase in harvesting. vpalmer@ Related Self-styled 'progressive B.C. government' picks fight with 10-year-old that it couldn't win B.C. backtracks and restores rare drug coverage for 10-year-old Charleigh Pollock
